ROBERT R RUFFOLO
CIK 1187308 · Sr. VP & Pres., Wyeth Research · last filed 2026-06-05
ROBERT R RUFFOLO is a Sr. VP & Pres., Wyeth Research who has filed 23 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for LBRX, was dated Jun 5, 2026. Across all open-market trades the lifetime net is −$7.7M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
6
23
-$7.68M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LBRX | Director | — | $28.42 | — | $0 | 2 | 2026-06-05 |
| ELTX | Director | — | $14.85 | — | $0 | 3 | 2025-05-20 |
| Sigilon Therapeutics, Inc. (SGTX) Delisted | Director | 6,750 | $22.47 | $151.7K | -$69.9K | 6 | 2023-08-11 |
| Aridis Pharmaceuticals, Inc. (ARDS) Delisted | Director | — | $0.31 | — | $0 | 3 | 2022-12-07 |
| CervoMed Inc. (DFFN) Delisted | Director | — | $6.60 | — | $0 | 3 | 2018-06-18 |
| WYETH (WYEp) Delisted | Sr. VP & Pres., Wyeth Research | 293,256 | — | — | -$7.61M | 6 | 2008-03-04 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | LBRX | Grant (A) | — | $0 | EDGAR |
| 2025-09-12 | LBRX | Mixed | — | $0 | EDGAR |
| 2025-05-20 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2024-11-25 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2023-12-29 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2023-08-11 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-05-22 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-12-07 | Aridis Pharmaceuticals, Inc. (ARDS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-27 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-10-05 | Aridis Pharmaceuticals, Inc. (ARDS) Delisted | Grant (A) | — | $0 | EDGAR |